CN107636468A - 用于预测认知退化的风险的方法 - Google Patents

用于预测认知退化的风险的方法 Download PDF

Info

Publication number
CN107636468A
CN107636468A CN201680032358.XA CN201680032358A CN107636468A CN 107636468 A CN107636468 A CN 107636468A CN 201680032358 A CN201680032358 A CN 201680032358A CN 107636468 A CN107636468 A CN 107636468A
Authority
CN
China
Prior art keywords
level
ferritin
patient
csf
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680032358.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·艾顿
N·福克斯
A·I·布什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crc Mental Health Co Ltd
Original Assignee
Crc Mental Health Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901210A external-priority patent/AU2015901210A0/en
Application filed by Crc Mental Health Co Ltd filed Critical Crc Mental Health Co Ltd
Publication of CN107636468A publication Critical patent/CN107636468A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0048—Detecting, measuring or recording by applying mechanical forces or stimuli
    • A61B5/0055—Detecting, measuring or recording by applying mechanical forces or stimuli by applying suction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
CN201680032358.XA 2015-04-02 2016-04-01 用于预测认知退化的风险的方法 Pending CN107636468A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015901210A AU2015901210A0 (en) 2015-04-02 Method for predicting risk of cognitive deterioration
AU2015901210 2015-04-02
AU2016900347A AU2016900347A0 (en) 2016-02-03 Method for predicting risk of cognitive deterioration
AU2016900347 2016-02-03
PCT/AU2016/050248 WO2016154682A1 (en) 2015-04-02 2016-04-01 Method for predicting risk of cognitive deterioration

Publications (1)

Publication Number Publication Date
CN107636468A true CN107636468A (zh) 2018-01-26

Family

ID=57003726

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680032358.XA Pending CN107636468A (zh) 2015-04-02 2016-04-01 用于预测认知退化的风险的方法

Country Status (9)

Country Link
US (1) US20180284141A1 (https=)
EP (1) EP3278113A4 (https=)
JP (1) JP2018513368A (https=)
KR (1) KR20170132318A (https=)
CN (1) CN107636468A (https=)
AU (1) AU2016240409A1 (https=)
BR (1) BR112017021098A2 (https=)
CA (1) CA2981533A1 (https=)
WO (1) WO2016154682A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109464122A (zh) * 2018-11-05 2019-03-15 西南大学 基于多模态数据的个体核心特质预测系统及方法
CN112353381A (zh) * 2020-11-24 2021-02-12 杭州冉曼智能科技有限公司 基于多模态大脑影像的阿尔茨海默症综合诊断系统
CN112526132A (zh) * 2020-11-23 2021-03-19 华中科技大学 预测2型糖尿病患者出现记忆力衰退的风险的方法
CN120089387A (zh) * 2025-05-07 2025-06-03 脑玺(苏州)智能科技有限公司 超早期认知下降状态的识别方法、装置及电子设备

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108496091B (zh) 2016-01-22 2021-09-10 圣纳普医疗公司 磁共振成像磁场依赖弛豫法系统和方法
WO2018064715A1 (en) * 2016-10-03 2018-04-12 Crc For Mental Health Ltd Method for predicting or diagnosing cognitive deterioration
US11690560B2 (en) 2016-10-24 2023-07-04 Akili Interactive Labs, Inc. Cognitive platform configured as a biomarker or other type of marker
WO2018084242A1 (ja) * 2016-11-02 2018-05-11 国立大学法人九州大学 アルツハイマー病のリスクの決定方法
JP7159188B2 (ja) * 2016-12-13 2022-10-24 アキリ・インタラクティヴ・ラブズ・インコーポレイテッド ナビゲーション課題を使用するバイオマーカーの識別およびナビゲーション課題を使用する治療のためのプラットフォーム
WO2018148788A1 (en) * 2017-02-17 2018-08-23 Crc For Mental Health Ltd Method for predicting risk and rate of amyloid deposition and plaque formation
WO2018176082A1 (en) * 2017-03-28 2018-10-04 Crc For Mental Health Ltd Predicting progression of cognitive deterioration
JP6199520B1 (ja) * 2017-04-11 2017-09-20 株式会社アルム 保険管理装置、および保険管理システム
US11234657B2 (en) * 2017-05-01 2022-02-01 Rhode Island Hospital Non-invasive measurement to predict post-surgery anterior cruciate ligament success
KR102076091B1 (ko) * 2017-08-30 2020-02-11 사회복지법인 삼성생명공익재단 기억성 경도인지장애(aMCI) 환자에 대한 아밀로이드 페트 검사 양성률 예측 방법 및 장치
WO2020069621A1 (en) * 2018-10-04 2020-04-09 University Of Manitoba Novel biomarker for alzheimer's disease in human
JP7334781B2 (ja) * 2019-06-28 2023-08-29 株式会社島津製作所 アミロイドβの脳内蓄積状態評価方法及び評価装置
US20220273184A1 (en) * 2019-08-20 2022-09-01 Terran Biosciences, Inc. Neuromelanin-sensitive mri for assessing parkinson's disease
JPWO2021039941A1 (https=) * 2019-08-30 2021-03-04
US11416776B2 (en) 2020-08-24 2022-08-16 Kpn Innovations, Llc. Method of and system for identifying and enumerating cross-body degradations
US11798652B2 (en) 2020-08-24 2023-10-24 Kpn Innovations, Llc. Method of and system for identifying and ameliorating body degradations
US11179110B1 (en) 2020-08-31 2021-11-23 Kpn Innovations Llc Method of system for reversing inflammation in a user
KR102406900B1 (ko) 2021-08-19 2022-06-08 의료법인 명지의료재단 노인 상태 개선 방법 및 시스템
KR102607398B1 (ko) * 2022-01-19 2023-11-29 이화여자대학교 산학협력단 뇌연령에 기초한 연령 관련 인지 저하 모니터링 방법 및 장치
CN114724709B (zh) * 2022-06-07 2022-10-14 深圳市铱硙医疗科技有限公司 基于vr眼动追踪的痴呆风险筛查系统、设备及介质
KR102771596B1 (ko) * 2022-07-14 2025-02-24 이화여자대학교 산학협력단 뇌영상으로부터 뇌성별 및 뇌연령을 예측하는 방법 및 장치

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102692A1 (en) * 2002-11-27 2004-05-27 General Electric Company Magnetic resonance imaging system and methods for the detection of brain iron deposits
CN1556815A (zh) * 2000-08-04 2004-12-22 �����ִ��ѧҽѧ���� 用作神经变性疾病诊断的铁调节蛋白-2
US20060030619A1 (en) * 2004-08-04 2006-02-09 University Of Utah Research Foundation Compositions and methods for chelation therapy
US20110236917A1 (en) * 2009-11-17 2011-09-29 Power3 Medical Products, Inc. Diagnosis of Alzheimer's Disease
CN103251932A (zh) * 2013-04-17 2013-08-21 钱忠明 铁调素在制备铁相关神经退行性疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123431D1 (de) * 2000-07-25 2006-11-09 Sir Mortimer B Davis Jewish Ge Ho-1 suppressor als diagnostischer und prognostischer test für demenz-krankheiten
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
US20050020904A1 (en) * 2003-07-10 2005-01-27 Cline Harvey Ellis System and method for the detection of brain iron using magnetic resonance imaging
WO2012027794A2 (en) * 2010-09-01 2012-03-08 The Mental Health Research Institute Of Victoria Method of treatment and agents useful for same
CN102743365A (zh) * 2011-04-19 2012-10-24 辽宁省计划生育科学研究院 一种化合物或其药学上可接受的盐在防治老年痴呆的应用
JP6084976B2 (ja) * 2011-09-06 2017-02-22 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド 組織内の異常物質の存在を検出するシステム及び方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1556815A (zh) * 2000-08-04 2004-12-22 �����ִ��ѧҽѧ���� 用作神经变性疾病诊断的铁调节蛋白-2
US20040102692A1 (en) * 2002-11-27 2004-05-27 General Electric Company Magnetic resonance imaging system and methods for the detection of brain iron deposits
US20060030619A1 (en) * 2004-08-04 2006-02-09 University Of Utah Research Foundation Compositions and methods for chelation therapy
US20110236917A1 (en) * 2009-11-17 2011-09-29 Power3 Medical Products, Inc. Diagnosis of Alzheimer's Disease
CN103251932A (zh) * 2013-04-17 2013-08-21 钱忠明 铁调素在制备铁相关神经退行性疾病药物中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASHLEY I.BUSH等: "EVIDENCE FOR APOE PROTECTING AGAINST BRAIN IRON OVERLOAD", 《ALZHEIMER"S & DEMENTIA》 *
AYTON,S等: "Biometals and Their Therapeutic Implications in Alzheimer"s Disease", 《NEUROTHERAPEUTICS》 *
GEORGE BARTZAOKIS等: "Brain ferritin iron may influence age- and gender-related risks of neurodegeneration", 《NEUROBIOLOGY OF AGING》 *
ZHU WZ等: "Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease", 《RADIOLOGY》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109464122A (zh) * 2018-11-05 2019-03-15 西南大学 基于多模态数据的个体核心特质预测系统及方法
CN112526132A (zh) * 2020-11-23 2021-03-19 华中科技大学 预测2型糖尿病患者出现记忆力衰退的风险的方法
CN112353381A (zh) * 2020-11-24 2021-02-12 杭州冉曼智能科技有限公司 基于多模态大脑影像的阿尔茨海默症综合诊断系统
CN112353381B (zh) * 2020-11-24 2022-06-28 杭州冉曼智能科技有限公司 基于多模态大脑影像的阿尔茨海默症综合诊断系统
CN120089387A (zh) * 2025-05-07 2025-06-03 脑玺(苏州)智能科技有限公司 超早期认知下降状态的识别方法、装置及电子设备

Also Published As

Publication number Publication date
EP3278113A1 (en) 2018-02-07
AU2016240409A1 (en) 2017-11-09
BR112017021098A2 (pt) 2018-07-03
KR20170132318A (ko) 2017-12-01
WO2016154682A1 (en) 2016-10-06
CA2981533A1 (en) 2016-10-06
JP2018513368A (ja) 2018-05-24
EP3278113A4 (en) 2018-11-21
US20180284141A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
CN107636468A (zh) 用于预测认知退化的风险的方法
Sánchez-Juan et al. Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
Park et al. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease
US20220057409A1 (en) Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair
JP2026016513A (ja) アルツハイマー病を判定するためのタンパク質マーカー
US10197580B2 (en) Biomarkers associated with schizophrenia
US20180120331A1 (en) Serum biomarker panels for bipolar disorder
Sakkaki et al. Gene expression patterns of CRYM and SIGLEC10 in Alzheimer's disease: potential early diagnostic indicators
Mak et al. Influence of alpha‐synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α‐synuclein seed amplification assay and FDG‐PET
Jakimovski et al. Disease biomarkers in multiple sclerosis: Current serum neurofilament light chain perspectives
WO2015019979A1 (ja) 統合失調症に関するバイオマーカー
US20120251553A1 (en) Biomarkers for schizophrenia or other psychotic disorders
JP2023509423A (ja) 神経変性状態のためのバイオマーカーとしてのキナーゼ
CN104487847B (zh) 与阿尔茨海默氏病和轻度认知障碍相关的原肌球蛋白同种型
Steinacker et al. Evidence for reduced synaptic protein SNAP-25 in cerebrospinal fluid in major depressive disorder and schizophrenia
JP7713445B2 (ja) 薬物誘発細胞毒性及び鬱病のバイオマーカー
WO2010005077A1 (ja) パーキンソン病の疾患関連たんぱく質およびその使用
WO2023068173A1 (ja) 脳内アミロイドβの蓄積を評価するためのバイオマーカー
Menne et al. Diagnose it yourself: will there be a home test kit for Alzheimer’s disease?
WO2016160484A1 (en) Novel biomarkers for psychiatric disorders
US20230280357A1 (en) Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
Abdi Discovery and Development of Biomarkers for Parkinson’s Disease and Related Disorders
van der Ende Fluid Biomarkers in Genetic Frontotemporal Dementia
den Braber et al. BRAIN COMMUNICATIONS
De Ryst et al. CSF Aquaporin-4 levels in controls and in idiopathic normal pressure hydrocephalus before and after shunt surgery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180126